The overall global diagnostics market to be worth over US$ 200 billion in 2024-25 with Point of care diagnostics contributing close to USD 43 billion. The market is experiencing significant growth driven by several key factors. The high prevalence of infectious diseases worldwide creates a need for early and accurate diagnosis, which, in turn, fuels the demand for home diagnostics and at-home test kits . Additionally, telemedicine and remote patient monitoring have become increasingly popular, facilitating the use of molecular diagnostic tools, in-vitro diagnostic tools, and point-of-care testing with human blood and tissue samples. The shortage of trained laboratory technicians in remote areas further emphasizes the importance of these advanced diagnostic solutions. This trend is expected to continue as technology evolves, making diagnostic testing more accessible and convenient for patients.

The global in vitro diagnostics market was size valued at $ 125 billion in 2024 and is growing at a CAGR of 4.82 % from 2025 to 2035. In vitro diagnostics refers to a category of medical tests and procedures that are conducted using samples of bodily fluids, tissues, or other specimens taken from a patient outside of their body. These tests are performed in a controlled laboratory environment, typically using specialized equipment and techniques.

At FutureWise, we help organizations switch to continuous decision-making by producing broader, deeper, and quicker insights from structured and unstructured data, private and public data with innovative technologies and advanced analytics technology. We aim to make corporate batch decision-making a more empowered, creative, and efficient continuum. We concentrate on sectors including life sciences and pharmaceutical corporations that must continuously assess and improve their efficiency, cut costs, and minimize risk to stay competitive.